Evidence map›Paper›PMID 38992454›Full record

ArticleSteroids2024

Synthesis and anticancer properties of a hybrid molecule with the testosterone and estradiol head-groups.

Alexis Paquin, Fayanne Nolin, Chahrazed Bouzriba, Sébastien Fortin, Irina F Sevrioukova, Gervais Bérubé

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Steroids, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alexis PaquinLaboratoire de Recherche en Chimie Médicinale (LRCM) et Groupe de Recherche en Signalisation Cellulaire (GRSC), Département de Chimie, Biochimie et Physique, Université du Québec à Trois-Rivières, C.P. 500, Trois-Rivières, QC, G9A 5H7, Canada.
Fayanne NolinLaboratoire de Recherche en Chimie Médicinale (LRCM) et Groupe de Recherche en Signalisation Cellulaire (GRSC), Département de Chimie, Biochimie et Physique, Université du Québec à Trois-Rivières, C.P. 500, Trois-Rivières, QC, G9A 5H7, Canada.
Chahrazed BouzribaCentre de Recherche du CHU de Québec-Université Laval, Axe Oncologie, Hôpital Saint-François d'Assise, 10 rue de l'Espinay, Québec, Québec, G1L 3L5, Canada; Faculté de Pharmacie, Université Laval, Québec, Québec, G1V 0A6, Canada.
Sébastien FortinCentre de Recherche du CHU de Québec-Université Laval, Axe Oncologie, Hôpital Saint-François d'Assise, 10 rue de l'Espinay, Québec, Québec, G1L 3L5, Canada; Faculté de Pharmacie, Université Laval, Québec, Québec, G1V 0A6, Canada.
Irina F SevrioukovaDepartment of Molecular Biology and Biochemistry, University of California, Irvine, CA, 92697, United States. Electronic address: sevrioui@uci.edu.
Gervais BérubéLaboratoire de Recherche en Chimie Médicinale (LRCM) et Groupe de Recherche en Signalisation Cellulaire (GRSC), Département de Chimie, Biochimie et Physique, Université du Québec à Trois-Rivières, C.P. 500, Trois-Rivières, QC, G9A 5H7, Canada. Electronic address: Gervais.Berube@uqtr.ca.

Funding

Toxicological importance of CYP3A4 catalysis and inhibitionR01ES025767 · NIEHS · UNIVERSITY OF CALIFORNIA-IRVINE · PI SEVRIOUKOVA, IRINA F · 2016 to 2025
$4.0M
NIEHS NIH HHS R01 ES025767
6 · The paper itself

Abstract

This is the first report on a unique hybrid molecule made of estradiol and testosterone (TS). This distinctive hybrid molecule (1) was designed to interact with both the estrogen receptor (ER) and the androgen receptor (AR) found in hormone-dependent female and male cancer cells, and was synthesized using ethynylestradiol (17EE) as the estrogenic component and 7α-(4-azido-but-2-enyl)-4-androsten-17β-ol-3-one as the androgenic counterpart in a seven-step reaction with ∼ 26 % overall yield. We reasoned that the dual receptor binding ability could allow 1 to act as an antihormone. This was tested on hormone-dependent and hormone-independent breast cancer (BCa) and prostate cancer (PCa) cells. The antiproliferative activity was also assessed on colon and skin cancer cells. We found that 1 was active against MCF7 (ER + ) BCa cells (IC

Indexed as

Antineoplastic AgentsCell ProliferationEstradiolTestosteroneCell Line, TumorDrug Screening Assays, AntitumorHumansMaleMolecular StructureReceptors, AndrogenReceptors, EstrogenStructure-Activity RelationshipAntineoplastic AgentsEstradiolReceptors, AndrogenReceptors, EstrogenTestosteroneBreast cancerColon cancerCYP3A4EstradiolHybrid moleculeMelanomaProstate cancerTestosterone

Identifiers

PMID38992454
PMCPMC11299231

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.